Home » Consortium EFPIA Companies » Bluebird Bio, United States

Bluebird Bio, United States

Partner Description

Bluebird Bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit. We’re putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent β-thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing. bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland.

Role within Project

  • Expertise in translational research in cancer immunotherapy with CAR T and TCR cells from target discovery and validation, through in vitro and in vivo preclinical development, and into the clinic
  • WP 2 Industry Lead for engineered T Cell MOA
  • Vested interest in WP 4 Biomarkers